Literature DB >> 8648329

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

C Colosimo1, M Merello, A J Hughes, K Sieradzan, A J Lees.   

Abstract

OBJECTIVES: To evaluate the contribution of postsynaptic changes to motor fluctuations, three groups of parkinsonian patients with differing responses to treatment were acutely challenged with two dopaminergic drugs-apomorphine and levodopa-having different mechanisms of action.
METHODS: Forty two patients with Parkinson's disease (14 untreated, eight with a stable response to levodopa, and 20 with levodopa induced motor fluctuations) were challenged on two consecutive days with apomorphine and levodopa. The latency, duration, and magnitude of motor response was measured.
RESULTS: A progressive shortening of mean latency after levodopa challenge was found passing from the untreated to the stable and fluctuating groups; the difference between untreated and fluctuating patients was statistically significant (P < 0.01). Response duration after levodopa challenge was similar in untreated and stable patients, whereas it showed a significant shortening in patients with motor fluctuations (P < 0.05 v both untreated and stable patients). When subcutaneous apomorphine was given, untreated patients had a longer response duration than those who had developed motor fluctuations (P < 0.05). Although baseline disability was significantly greater in the fluctuating patients than in the untreated and stable patients, the severity of residual parkinsonian signs after both apomorphine and levodopa challenge was similar for all three groups; as a result, the degree of improvement in parkinsonian signs after dopaminergic stimulation was substantially greater in more advanced than in early cases. Linear regression analysis also indicated that latency and duration after apomorphine challenge did not significantly correlate with those after levodopa challenge, whereas magnitude of response to apomorphine showed a strong positive correlation with that after levodopa challenge (r = 0.9, P < 0.001).
CONCLUSION: The progressive shortening of motor response after both apomorphine and levodopa suggests that pharmacodynamic factors play an important part in determining the duration of motor response and argue against altered central pharmacokinetics of levodopa being principally responsible for the on-off effect. The widening response amplitude and increasing off phase disability occurring during disease progression are also critical factors in determining the appearance of motor fluctuations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648329      PMCID: PMC1073946          DOI: 10.1136/jnnp.60.6.634

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  25 in total

1.  Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.

Authors:  F Grandas; S T Gancher; M Rodriguez; G Lera; J G Nutt; J A Obeso
Journal:  Clin Neuropharmacol       Date:  1992-02       Impact factor: 1.592

2.  Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.

Authors:  J Vaamonde; M R Luquin; J A Obeso
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

3.  "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.

Authors:  S Fahn
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

4.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

Authors:  M D Muenter; G M Tyce
Journal:  Mayo Clin Proc       Date:  1971-04       Impact factor: 7.616

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Dopamine receptors in the Parkinsonian brain.

Authors:  U K Rinne; P Lönnberg; V Koskinen
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years.

Authors:  A J Hughes; J P Frankel; P A Kempster; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-04       Impact factor: 10.154

8.  Response of patients with postencephalitic Parkinsonism to levodopa.

Authors:  R C Duvoisin; J Lobo-Antunes; M D Yahr
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-08       Impact factor: 10.154

Review 9.  Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.

Authors:  A J Hughes; A J Lees; G M Stern
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

10.  Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.

Authors:  J G Nutt; W R Woodward; J H Carter; S T Gancher
Journal:  Arch Neurol       Date:  1992-11
View more
  10 in total

1.  Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

Authors:  John G Nutt; Kathy A Chung; Nicholas H G Holford
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

Review 2.  Parkinson's disease: medical treatment of moderate to advanced disease.

Authors:  Oksana Suchowersky
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 3.  Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

Authors:  Sean S O'Sullivan; Andrew H Evans; Andrew J Lees
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Impaired gastric myoelectrical activity in patients with Parkinson's disease and effect of levodopa treatment.

Authors:  Ching-Liang Lu; Din-E Shan; Chih-Yen Chen; Jiing-Chyuan Luo; Full-Young Chang; Shou-Dong Lee; Han-Chang Wu; J D Z Chen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 5.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Pharmacodynamics of a low subacute levodopa dose helps distinguish between multiple system atrophy with predominant Parkinsonism and Parkinson's disease.

Authors:  Giovanna Calandra-Buonaura; Andrea Doria; Giovanna Lopane; Pietro Guaraldi; Sabina Capellari; Paolo Martinelli; Pietro Cortelli; Manuela Contin
Journal:  J Neurol       Date:  2015-11-14       Impact factor: 4.849

7.  Loss of presynaptic inhibition for step initiation in parkinsonian individuals with freezing of gait.

Authors:  Jumes Leopoldino Oliveira Lira; Carlos Ugrinowitsch; Daniel Boari Coelho; Luis Augusto Teixeira; Andrea Cristina de Lima-Pardini; Fernando Henrique Magalhães; Egberto Reis Barbosa; Fay B Horak; Carla Silva-Batista
Journal:  J Physiol       Date:  2020-03-12       Impact factor: 5.182

8.  Advanced Therapies for the Management of Dopamine Dysregulation Syndrome in Parkinson's Disease.

Authors:  Sanskriti Sasikumar; Roberto Matta; Renato P Munhoz; Mateusz Zurowski; Yu-Yan Poon; Mojgan Hodaie; Suneil K Kalia; Andres M Lozano; Alfonso Fasano
Journal:  Mov Disord Clin Pract       Date:  2021-03-11

9.  Evaluation of the objective posturo-locomotor-manual method in patients with parkinsonian syndromes.

Authors:  Theresa Zackrisson; Filip Bergquist; Björn Holmberg; Bo Johnels; Thorleif Thorlin
Journal:  Front Neurol       Date:  2013-07-19       Impact factor: 4.003

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.